NEODOSE

INDICATIONS

Iron supplementation in patients unable to tolerate oral iron, especially those also being treated with erythropoietin.

ADVERSE EFFECTS

No adverse effects have been observed in patients who have received low doses infused continuously. Large (50-mg) intramuscular doses administered to infants were associated with increased risk of infection. Retrospective reviews of adult patients who received larger doses injected over a few minutes report a 0.7% risk of immediate serious allergic reactions, and a 5% risk of delayed such as myalgia, arthralgia, phlebitis, and lymphadenopathy.

BLACK BOX WARNING

Anaphylactic-type reactions, including fatalities, have followed parenteral administration. Resuscitation equipment and trained personnel must be readily available during iron dextran administration. Must perform test dose. Observe for signs/symptoms of anaphylactic-type reactions. Fatal reactions have occurred following the test dose and have occurred in situations where the test dose was tolerated. Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions.

ADMINISTRATION

For continuous infusion, iron dextran may be added to peripheral nutrition solutions. The solution must contain an amino acid final concentration of at least 2%.

MONITORING

Periodic CBC and reticulocyte count. Observe Dex/AA solution for rust-colored precipitates.